ROCKLAND, Mass., May 21, 2015 /PRNewswire/ — EMD Serono, Inc., the U.S. biopharmaceuticals business of Merck KGaA, Darmstadt, Germany, announced today that data about Rebif® (interferon beta-1a), the company’s high-dose, high-frequency interferon beta for relapsing forms of multiple sclerosis, will be presented at the 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), taking place from May 27-30 in Indianapolis, Indiana.
Data from 11 abstracts to be presented assess the efficacy of Rebif (interferon beta-1a) on MRI and clinical outcomes, and evaluate early predictors of no evidence of disease activity (NEDA) response, among other measures. The data also explores real-world evidence in MS, with analysis of time to first treatment with disease modifying drug as well as trends in treatment adherence among patients treated with self-injectables versus oral therapies.
“EMD Serono continues to evaluate the patient outcomes of Rebif, more specifically the important role it plays in the lives of those living with MS,” said Dr. Rick Munschauer, Vice President, Medical Affairs, Neurology and Immunology, EMD Serono. “Our scientific and medical presence at this year’s CMSC Annual Meeting is aimed at enhancing the understanding of our product and its effect on key measures in MS to help optimize patient care.”
~~~~~~~~~~~~~~~~~~~~
.
.
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews